<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00073853</url>
  </required_header>
  <id_info>
    <org_study_id>22-P-01</org_study_id>
    <nct_id>NCT00073853</nct_id>
  </id_info>
  <brief_title>Autologous Incubated Macrophages for Patients With Complete Spinal Cord Injuries</brief_title>
  <official_title>A Phase II Multicenter, Randomized-Controlled Study to Evaluate the Safety and Efficacy of Autologous Incubated Macrophages for the Treatment of Patients With Complete Spinal Cord Injuries</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Proneuron Biotechnologies</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Marcus Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>B.I.R.D. (Israel-U.S. Binational Industrial Research and Development)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Proneuron Biotechnologies</source>
  <brief_summary>
    <textblock>
      Autologous Incubated Macrophages (ProCord) is being developed as a therapy for acute,
      complete spinal cord injury (SCI). The therapy is intended to reverse the loss of motor and
      sensory function.

      Following non-CNS tissue injury, macrophages quickly arrive on the scene, where they clean up
      cell debris, secrete different molecules thus promoting a controlled inflammatory reaction
      that forms the first phase of the wound healing process. While this process occurs in most
      tissues, including peripheral nerves, it does not occur in the CNS, where macrophages and
      other immune cells are relatively rare, and their activities curtailed by a biochemical
      mechanism known as &quot;immune privilege.&quot;

      In animal studies, it appears that incubated macrophages circumvent the immune privilege,
      thus supporting the regrowth of axons through the injury site and enabling the recovery of
      neurological function. The concept derives from the pioneering research of Prof. Michal
      Schwartz at the Weizmann Institute of Science.
    </textblock>
  </brief_summary>
  <overall_status>Suspended</overall_status>
  <start_date>September 2003</start_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement of ASIA grade</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sensory scores</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Motor scores</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bladder and bowel function</measure>
  </secondary_outcome>
  <enrollment>61</enrollment>
  <condition>Spinal Cord Injury</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Autologous Incubated Macrophages (cell therapy)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Traumatic SCI during last 14 days

          -  Age 16 to 65 years

          -  Complete spinal cord injury (ASIA A)

          -  Neurological level : C5 to T11

          -  MRI showing lesion

        Exclusion Criteria:

          -  Women who are pregnant or breastfeeding

          -  Coma or other severe injury or disease

          -  Penetrating injury

          -  Ongoing mechanical ventilation

          -  Unsuitable based on MRI or other factor
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel Lammertse, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Craig Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nachshon Knoller, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Chaim Sheba Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marca Sipski, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>University of Miami</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Edward Benzel, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>The Cleveland Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Craig Hospital</name>
      <address>
        <city>Englewood</city>
        <state>Colorado</state>
        <zip>80110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shepherd Center</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30309</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMDNJ</name>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <zip>07103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kessler Medical Rehabilitation Research and Education Corporation</name>
      <address>
        <city>West Orange</city>
        <state>New Jersey</state>
        <zip>07052</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Spinal Cord Injury Model System</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shriners Hospital for Children</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19140</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chaim Sheba Medical Center</name>
      <address>
        <city>Tel Hashomer</city>
        <zip>52621</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Knoller N, Auerbach G, Fulga V, Zelig G, Attias J, Bakimer R, Marder JB, Yoles E, Belkin M, Schwartz M, Hadani M. Clinical experience using incubated autologous macrophages as a treatment for complete spinal cord injury: phase I study results. J Neurosurg Spine. 2005 Sep;3(3):173-81.</citation>
    <PMID>16235699</PMID>
  </reference>
  <reference>
    <citation>Bomstein Y, Marder JB, Vitner K, Smirnov I, Lisaey G, Butovsky O, Fulga V, Yoles E. Features of skin-coincubated macrophages that promote recovery from spinal cord injury. J Neuroimmunol. 2003 Sep;142(1-2):10-6.</citation>
    <PMID>14512160</PMID>
  </reference>
  <reference>
    <citation>Rapalino O, Lazarov-Spiegler O, Agranov E, Velan GJ, Yoles E, Fraidakis M, Solomon A, Gepstein R, Katz A, Belkin M, Hadani M, Schwartz M. Implantation of stimulated homologous macrophages results in partial recovery of paraplegic rats. Nat Med. 1998 Jul;4(7):814-21.</citation>
    <PMID>9662373</PMID>
  </reference>
  <verification_date>March 2006</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 10, 2003</study_first_submitted>
  <study_first_submitted_qc>December 10, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 11, 2003</study_first_posted>
  <last_update_submitted>August 27, 2009</last_update_submitted>
  <last_update_submitted_qc>August 27, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 28, 2009</last_update_posted>
  <keyword>paraplegia</keyword>
  <keyword>quadraplegia</keyword>
  <keyword>tetraplegia</keyword>
  <keyword>paralysis</keyword>
  <keyword>nerve regeneration</keyword>
  <keyword>Acute, Complete SCI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Wounds and Injuries</mesh_term>
    <mesh_term>Spinal Cord Injuries</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

